American Journal of Cardiovascular Drugs

, Volume 4, Supplement 1, pp 7–11

Nouvelles recommandations américaines : analyse critique

Review Article


Le Joint National Committee aux Etats-Unis a récemment publié son septième rapport. Celui-ci comprend un certain nombre de modifications importantes en ce qui concerne la prise en charge de l’hypertension artérielle et notamment l’introduction du concept de « préhypertension », le choix du traitement médicamenteux initial, l’utilisation d’associations thérapeutiques dès la première intention et l’abaissement des cibles du traitement. Cet article présente et argumente ces nouvelles approches.


The new American Guidelines: Critical Analysis

The recently published seventh U.S. Joint National Committee report comprises a number of important changes regarding the management of hypertension, including the addition of the concept of “prehypertension”, the choice of initial drug therapy, the use of combinations for initial therapy and lower goals for therapy. These and other changes are described and defended.


  1. 1.
    Chobanian AV, Bakris GL, Black HR, et al. for the Joint National Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC-7 Report. JAMA 2003; 289: 2560–72PubMedCrossRefGoogle Scholar
  2. 2.
    Joint National Committee. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413–46CrossRefGoogle Scholar
  3. 3.
    Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension. 2004; 43: 10–7PubMedCrossRefGoogle Scholar
  4. 4.
    Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289: 2363–9PubMedCrossRefGoogle Scholar
  5. 5.
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002; 360: 1903–13PubMedCrossRefGoogle Scholar
  6. 6.
    Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, et al. Health-related quality of life of subjects with known and unknown hypertension: Results from the population-based Hortega study. J Hypertens 2003; 21: 1283–9PubMedCrossRefGoogle Scholar
  7. 7.
    Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003–10PubMedCrossRefGoogle Scholar
  8. 8.
    Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 2002; 2888: 1882–8CrossRefGoogle Scholar
  9. 9.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981–97CrossRefGoogle Scholar
  10. 10.
    Kaplan NM. “Treatment of Hypertension: Drug Therapy.” Chapter 7 in Kaplan’s Clinical Hypertension, 8th ed. Philadelphia: Lippincott Williams & Wilkins. 2002. pp 309–312Google Scholar
  11. 11.
    Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network metaanalysis. JAMA 2003; 289: 2534–44PubMedCrossRefGoogle Scholar
  12. 12.
    Kuo S-W, Dee P, Hung Y-J, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens 2003; 16: 623–8PubMedCrossRefGoogle Scholar
  13. 13.
    Bakris GL, Williams M, Dworkin L, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes. Am J Kidney Dis 2000; 36: 646–61PubMedCrossRefGoogle Scholar
  14. 14.
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393–404CrossRefGoogle Scholar
  15. 15.
    Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35: 539–43PubMedCrossRefGoogle Scholar
  16. 16.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62PubMedCrossRefGoogle Scholar
  17. 17.
    Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36). Br Med J 2000; 321: 412–9CrossRefGoogle Scholar
  18. 18.
    Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 2003; 139: 244–52PubMedGoogle Scholar
  19. 19.
    Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants in the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218–25PubMedGoogle Scholar
  20. 20.
    Wright JT Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288: 2421–31PubMedCrossRefGoogle Scholar
  21. 21.
    Mulrow CD, Townsend RR. Guiding lights for antihypertensive treatment in patients with nondiabetic chronic renal disease: Proteinuria and blood pressure levels? Ann Intern Med 2003; 139: 296–8PubMedGoogle Scholar
  22. 22.
    Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759–66PubMedCrossRefGoogle Scholar
  23. 23.
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53CrossRefGoogle Scholar
  24. 24.
    The EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (The EUROPA study). Lancet 2003; 362: 782–8CrossRefGoogle Scholar
  25. 25.
    Sachs FM, Svetkey LP, Vollmer WM, et al., for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3–10CrossRefGoogle Scholar
  26. 26.
    Trichopoulou A, Costacou T, Bamia C, et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348: 2599–608PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.The University of Texas Southwestern Medical Center at DallasDallasUSA

Personalised recommendations